Head-to-head · free

Doximity, Inc. vs Eton Pharmaceuticals, Inc.

DOCS vs ETON — return on capital, cash generation, margins and balance sheet side by side.

DOCS

8 / 9

measures where DOCS leads

ETON

1 / 9

measures where ETON leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureDOCS · FY2026ETON · FY2025
Revenue$644.9M$80.0M
Net income$196.1M(4.6M)
Revenue growth (yearly, multi-year)17.0%38.3%
Free cash flow$326.5M$10.2M
Free cash flow margin50.6%12.7%
Net cash / (debt)——
ROIC16.4%—
Return on equity19.3%-18.2%
Gross margin89.1%53.5%
Operating margin33.3%-1.1%
Net debt / EBITDA-0.96x1.44x

Figures are as reported by each company; latest fiscal year shown.

Where Doximity, Inc.'s cash went (FY2026)

Capital spending
$0
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full DOCS profile →

Where Eton Pharmaceuticals, Inc.'s cash went (FY2025)

Capital spending
$333000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full ETON profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons